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Background: Bone marrow adipose tissue (MAT) contributes to increased circulating 
adiponectin, an insulin-sensitizing hormone, during caloric restriction (CR), but whether 
this occurs in other contexts remains unknown. The antidiabetic thiazolidinediones 
(TZDs) also promote MAT expansion and hyperadiponectinemia, even without increasing 
adiponectin expression in white adipose tissue (WAT).
Objectives: To test the hypothesis that MAT expansion contributes to TZD-associated 
hyperadiponectinemia, we investigated the effects of rosiglitazone, a prototypical TZD, in 
wild-type (WT) or Ocn-Wnt10b mice. The latter resist MAT expansion during CR, leading 
us to postulate that they would also resist this effect of rosiglitazone.
Design: Male and female WT or Ocn-Wnt10b mice (C57BL/6J) were treated with or 
without rosiglitazone for 2, 4, or 8 weeks, up to 30 weeks of age. MAT content was 
assessed by osmium tetroxide staining and adipocyte marker expression. Circulating 
adiponectin was determined by ELISA.
results: In WT mice, rosiglitazone caused hyperadiponectinemia and MAT expansion. 
Compared to WT mice, Ocn-Wnt10b mice had significantly less MAT in distal tibiae and 
sometimes in proximal tibiae; however, interpretation was complicated by the leakage 
of osmium tetroxide from ruptures in some tibiae, highlighting an important technical 
consideration for osmium-based MAT analysis. Despite decreased MAT in Ocn-Wnt10b 
mice, circulating adiponectin was generally similar between WT and Ocn-Wnt10b mice; 
however, in females receiving rosiglitazone for 4  weeks, hyperadiponectinemia was 
significantly blunted in Ocn-Wnt10b compared to WT mice. Notably, this was also the 
only group in which tibial adiponectin expression was lower than in WT mice, suggesting 
a close association between MAT adiponectin production and circulating adiponectin. 
However, rosiglitazone significantly increased adiponectin protein expression in WAT, 
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suggesting that WAT contributes to hyperadiponectinemia in this context. Finally, 
rosiglitazone upregulated uncoupling protein 1 in brown adipose tissue (BAT), but this 
protein was undetectable in tibiae, suggesting that MAT is unlikely to share thermogenic 
properties of BAT.
conclusion: TZD-induced hyperadiponectinemia is closely associated with increased 
adiponectin production in MAT but is not prevented by the partial loss of MAT that 
occurs in Ocn-Wnt10b mice. Thus, more robust loss-of-MAT models are required for 
future studies to better establish MAT’s elusive functions, both on an endocrine level and 
beyond.
Keywords: bone marrow adipose tissue, white adipose tissue, brown adipose tissue, thiazolidinedione, 
rosiglitazone, adiponectin, beige adipocyte, UcP1
inTrODUcTiOn
Adipose tissue is typically classified into two broad subtypes, white 
adipose tissue (WAT) and brown adipose tissue (BAT). WAT is 
commonly known for its role in energy storage and release and is 
now established as a major endocrine organ. BAT also mediates 
some endocrine functions but is more widely known for its ability 
to mediate adaptive thermogenesis (1). Through these functions, 
both WAT and BAT impact metabolic homeostasis; hence, the 
global burden of obesity and metabolic disease has motivated 
extensive study of these tissues (2).
In addition to WAT and BAT, adipocytes also exist in the 
bone marrow, and such marrow adipose tissue (MAT) has been 
estimated to account for over 10% of total adipose tissue mass in 
lean, healthy humans (3). We recently revealed that MAT char-
acteristics are region-specific, such that MAT can be classified 
into two broad subtypes: regulated MAT (rMAT), which exists 
in more proximal skeletal sites and consists of adipocytes inter-
spersed with hematopoietic BM; and constitutive MAT (cMAT), 
which exists in more distal regions (e.g., distal tibia, caudal 
vertebrae) and appears histologically similar to WAT, with few 
visible hematopoietic cells (4). These MAT subtypes also differ in 
their lipid composition and response to external stimuli (4). Both 
rMAT and cMAT appear to be developmentally and functionally 
distinct to WAT and BAT, and therefore MAT may represent a 
third general class of adipose tissue (5, 6). Despite these advances, 
knowledge of MAT formation and function remains relatively 
limited (2). However, research from others and us suggests that, 
like WAT, MAT is an endocrine organ that can exert local and 
systemic effects (3, 7).
The appreciation of WAT as an endocrine organ derives largely 
from the discovery in the mid-1990s of two adipocyte-derived 
hormones, leptin and adiponectin, each of which impacts meta-
bolic homeostasis (8–10). These two hormones have since been 
mentioned in over 40,000 publications, reflecting the extensive 
depth of WAT research. Circulating leptin concentrations corre-
late directly with body fat percentage and are therefore increased 
in obesity. In contrast, adiponectin concentrations are decreased 
in obesity and insulin-resistance; hence, hypoadiponectinemia is 
now an established biomarker for increased risk of cardiometa-
bolic disease. Conversely, circulating adiponectin is elevated in 
conditions of leanness and insulin sensitivity, such as during 
caloric restriction (CR) (2). This counterintuitive observation has 
been dubbed the “adiponectin paradox”: why should circulating 
adiponectin increase when the amount of WAT, the presumed 
source of adiponectin, is decreased? Moreover, CR can cause 
hyperadiponectinemia without increasing expression or secre-
tion of adiponectin from WAT (2), suggesting that other tissues 
contribute to this effect. Our recent research has highlighted a 
potential explanation for this paradox, revealing, unexpectedly, 
that MAT is a source of circulating adiponectin during CR (3).
Our studies into MAT and CR were motivated by the striking 
observation that, in contrast to WAT and BAT, MAT accumu-
lates during CR (3, 11, 12). The biochemical phenotype of this 
CR-responsive MAT remains to be elucidated; however, we 
have since shown that these increases occur predominantly in 
regions of rMAT rather than cMAT (2). This phenomenon led 
us to investigate if MAT contributes to increased circulating 
adiponectin during CR. After confirming that MAT expresses 
and secretes adiponectin (3), we then tested if MAT accumula-
tion is required for CR-associated hyperadiponectinemia. To do 
so, we used Ocn-Wnt10b mice, a transgenic model in which the 
secreted ligand, Wnt10b, is expressed in osteoblasts from the Ocn 
promoter (13). Because Wnt10b simulates osteoblastogenesis and 
inhibits adipogenesis, these mice have increased bone formation 
and decreased bone marrow volume (3, 13). We found that 
Ocn-Wnt10b mice also resist CR-associated MAT expansion, 
both in rMAT and cMAT (2, 3). Notably, hyperadiponectinemia 
during CR is also blunted in these mice, despite no differences 
in adiponectin expression in WAT (3). Finally, impaired MAT 
expansion also coincides with blunted hyperadiponectinemia 
in a separate mouse model of CR (14) and during CR in rabbits 
(12). Together, these observations suggest that MAT expansion is 
required for CR-induced hyperadiponectinemia, supporting the 
conclusion that MAT is a source of circulating adiponectin in this 
context.
To further investigate this endocrine function, we sought 
to determine if MAT also influences circulating adiponectin 
beyond CR. For example, increases in both MAT and circulating 
adiponectin occur in many other conditions, including aging, 
estrogen deficiency, type 1 diabetes, cancer treatment, and in 
response to fibroblast growth factor-21 or glucocorticoid therapy 
TaBle 1 | summary of groups for control or TZD treatment.
Weeks of 
TZD
ages (weeks) 
fed Western diet 
(D12450B)
ages (weeks)  
fed TZD diet 
(D12112601)
group sizes for each sex 
and genotype
0 22–30 N/A WT male, 5; Ocn-Wnt10b 
male, 5
WT female, 6; Ocn-Wnt10b 
female, 4
2 22–28 28–30 WT male, 3; Ocn-Wnt10b 
male, 7
WT female, 5; Ocn-Wnt10b 
female, 3
4 22–26 26–30 WT male, 5; Ocn-Wnt10b 
male, 5
WT female, 5; Ocn-Wnt10b 
female, 3
8 N/A 22–30 WT male, 5; Ocn-Wnt10b 
male, 5
WT female, 4; Ocn-Wnt10b 
female, 5
3
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(2). Notably, these increases also coincide during treatment with 
thiazolidinediones (TZDs), a class of insulin-sensitizing, antidia-
betic drugs that act as agonists for the nuclear hormone receptor, 
peroxisome proliferator-activated receptor gamma (PPARγ) (15, 
16). Binding and subsequent activation of PPARγ causes it to 
activate the expression of its transcriptional targets, including 
adiponectin and other lipid-metabolism-associated genes such 
as fatty acid-binding protein 4 (Fabp4) (17). Thus, TZDs, such 
as rosiglitazone, significantly increase circulating adiponectin 
in rodent models and human patients (18, 19). Importantly, 
preclinical studies suggest that such hyperadiponectinemia is 
required for the full insulin-sensitizing effects of TZDs (20). 
Despite the beneficial effects of TZDs in improving glucose toler-
ance, their clinical use has been restricted owing to increased risk 
of myocardial infarction and bone fractures (21, 22); the latter 
may relate to the ability of TZDs to drive MAT expansion. If so, 
MAT expansion may be detrimental to the clinical utility of these 
drugs. However, it is notable that TZDs can increase circulating 
adiponectin without increasing adiponectin expression in WAT 
(23, 24), and that some studies suggest that TZD action is inde-
pendent of WAT (25). Thus, given the contribution of MAT to 
increased circulating adiponectin during CR, we hypothesized 
that MAT also contributes to TZD-induced hyperadiponectine-
mia. If so, MAT expansion may play a role in the beneficial 
insulin-sensitizing effects of TZDs.
Herein, we investigated this hypothesis by feeding wild-type 
(WT) and Ocn-Wnt10b mice a Western diet to induce obesity and 
glucose intolerance, followed by treatment with rosiglitazone, a 
prototypical TZD. We postulated that, as in CR, these mice would 
resist TZD-induced MAT expansion. As secondary analyses, we 
also investigated the contribution of WAT to TZD-mediated 
hyperadiponectinemia and the possibility, suggested previously 
(26), that MAT has BAT-like properties. Our results shed light 
on MAT’s characteristics and highlight technical considerations 
that will be important for future research into MAT formation 
and function.
MaTerials anD MeThODs
animals and animal care
Ocn-Wnt10b mice (Wnt10b) or non-transgenic controls (WT) 
were on a C57BL/6J background and were bred in-house, as 
described previously (13). The University of Michigan Committee 
on the Use and Care of Animals approved all animal experiments, 
with daily care of mice and rabbits overseen by the Unit for 
Laboratory Animal Medicine (ULAM).
Diets and rosiglitazone (TZD) Treatment
Male WT (n = 18), male Wnt10b (n = 22), female WT (n = 20), 
and female Wnt10b (n = 15) mice were fed a standard labora-
tory chow diet (Research Diets, D12450B) from weaning until 
10 weeks of age. From 10 to 22 weeks of age, all mice were fed a 
high-fat, high-sucrose Western diet (Research Diets D12079B), 
with the goal of promoting diet-induced obesity and glucose 
intolerance. The rationale for this was that, if Ocn-Wnt10b mice 
resisted hyperadiponectinemia, they might also be less responsive 
to the metabolic effects of TZD treatment. Thus, mice were fed 
a Western diet prior to TZD treatment, with the aim of allowing 
detection of metabolic improvements upon TZD administration. 
At 18 weeks of age, mice were fasted overnight; body mass and 
fasting glucose were then recorded and body fat, lean mass, 
and free fluid were measured in conscious mice using an NMR 
analyzer (Minispec LF90II; Bruker Optics, Billerica, MA, USA). 
These measurements were then used as a basis to assign mice 
to four evenly matched groups (with similar body mass, fat 
mass, and fasting glucose), with each group corresponding to a 
different duration of rosiglitazone (TZD) treatment. Mice were 
then treated with or without TZD from 22 to 30 weeks of age. 
TZD was administered in the diet (Research Diets D12112601) 
by supplementing diet D12450B with rosiglitazone at 0.175 mg/g 
diet; based on daily consumption of D12450B, this concentration 
was estimated to give a final dose per mouse of 15 mg/kg body 
mass per day. This approach is similar to that used in previous 
studies investigating rosiglitazone-induced MAT accumulation 
(26–28). The four experimental groups were as follows: control 
mice (0 weeks’ TZD), which continued to receive Western diet 
D12079B from 22 to 30 weeks of age; 2 weeks’ TZD mice, which 
received D12079B from 22 to 28 weeks and D12112601 from 28 
to 30 weeks; 4 weeks’ TZD mice, which received D12079B from 
22 to 26 weeks and D12112601 from 26 to 30 weeks; and 8 weeks’ 
TZD mice, which received D12112601 from 22 to 30  weeks. 
Numbers of mice per group and diet durations are described 
further in Table 1. At 29.5 weeks of age, blood glucose concentra-
tions were recorded after an overnight fast to assess the effects of 
TZD treatment. At 30  weeks of age, serum was sampled, mice 
were humanely euthanized, and tissues were isolated for further 
analysis.
Blood collection and serum  
adiponectin analysis
Blood was sampled from the lateral tail vein of mice using 
Microvette CB 300 capillary collection tubes (Sarstedt, Newton, 
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NC, USA). Blood glucose was measured using an Accu-Chek 
Aviva glucometer. To obtain serum, blood samples were allowed 
to clot on ice for 2 h before centrifuging at 3,800 RCF for 5 min 
at 4°C. Serum adiponectin was determined using an ELISA kit 
(catalog no. MRP300) from R&D Systems (Bio-Techne Ltd., 
Abingdon, UK) according to the manufacturer’s instructions.
Osmium Tetroxide staining  
and μcT analysis
Tibiae were isolated and, after removal of external soft tissue, fixed 
in formalin at 4°C. Fixed tibiae were decalcified in 14% EDTA for 
14 days and then washed in Sorensen’s Phosphate buffer (81 mM 
KH2PO4, 19  mM Na2HPO4  ⋅  7H2O, pH 7.4). Decalcified tibiae 
were stored in Sorensen’s Phosphate buffer at 4°C until ready to be 
stained with osmium tetroxide. To do so, osmium tetroxide solu-
tion (2% w/v; Agar Scientific, UK) was diluted 1:1 in Sorensen’s 
Phosphate buffer. Tibiae were then stained in this 1% osmium 
tetroxide solution for 48  h at room temperature, then washed, 
and stored in Sorensen’s Phosphate buffer at 4°C prior to micro 
computed tomography (μCT) analysis.
Micro computed Tomography analysis
Layers of four to five stained tibiae were arranged in parallel 
in 1% agarose in a 30-mL universal tube and mounted in a 
Skyscan 1172 desktop micro CT (Bruker, Kontich, Belgium). 
The samples were then scanned through 360° using a step of 
0.40° between exposures. A voxel resolution of 12.05 μm was 
obtained in the scans using the following control settings: 54 kV 
source voltage, 185 μA source current with an exposure time 
of 885 ms. A 0.5-mm aluminum filter and two-frame averaging 
were used to optimize the scan. After scanning, the data were 
reconstructed using Skyscan software NRecon v1.6.9.4 (Bruker, 
Kontich, Belgium). The reconstruction thresholding window 
was optimized to encapsulate the target image. Volumetric 
analysis was performed using CT Analyser v1.13.5.1 (Bruker, 
Kontich, Belgium).
real-time Quantitative Pcr
RNA was extracted from tissue using RNA STAT60 reagent (Tel-
Test, Inc.) according to the manufacturer’s instructions. Synthesis 
of cDNA was done using TaqMan reverse transcription reagents 
(Thermo Fisher Scientific) using 1 μg of RNA template per reac-
tion, as per manufacturer’s instructions. Transcript expression 
was then analyzed by quantitative PCR (qPCR) in 10 μL duplicate 
reactions using qPCRBIO SyGreen Mix (part number PB20.11; 
PCR Biosystems, UK) and 1–4 μL of cDNA template. Reactions 
were loaded into 384-well qPCR plates (part number 72.1985.202; 
Sarstedt, UK) and run on a Light Cycler 480 (Roche). Transcript 
expression was calculated based on a cDNA titration loaded on 
each plate and was presented relative to expression of the house-
keeping gene Ppia. Primers for Adipoq and Ppia were described 
and validated previously (3).
immunoblot analysis
Frozen tissue was processed as described previously (12). The 
resulting protein lysates were separated by size using gradient 
(4–12%) polyacrylamide gels (BioRad). Protein was then trans-
ferred to Immobilon-FL membrane (Millipore) for 150  min at 
350  mA, 4°C, using a Criterion wet-transfer system (BioRad). 
Post-transfer, the membranes were blocked in 5% milk for 1 h at 
room temperature, then immunoblotted with primary antibody 
in 5% bovine serum albumin overnight at 4°C. Membranes were 
then incubated in 1:15,000-diluted fluorescently labeled second-
ary antibody (LiCor) for 1  h at room temperature. Signal was 
detected using the LiCor Odyssey system and band intensities 
quantified using LiCor Image Studio Lite software. The following 
primary antibodies were used: rabbit anti-adiponectin antibody 
(Sigma, A6354-200UL) diluted 1:1,000 in 5% BSA; rabbit anti-
uncoupling protein 1 (UCP1) antibody (Sigma, U6382) diluted 
1:10,000 in 2.5% milk; and rabbit anti-β-actin antibody (Abcam, 
ab8227) diluted 1:1,000 in 5% BSA.
Data Presentation and statistical analysis
Data are presented as box and whisker plots overlaid with 
individual data points for each animal. Boxes indicate the 25th 
and 75th percentiles; whiskers display the range; and horizontal 
lines in each box represent the median. Group sizes are described 
in Table 1. Statistical analysis was done using GraphPad Prism 
6 software, with significant differences assessed by two-way 
ANOVA using a Tukey or Sidak post hoc test for multiple com-
parisons, as appropriate. A P-value <0.05 was considered statisti-
cally significant. A significant influence of TZD treatment, across 
all treatment groups, is indicated by †. For multiple comparisons, 
asterisks (*) indicate significant differences between genotypes 
within each TZD group, while hash signs (#) indicate significance 
between TZD-treated and non-TZD-treated controls within each 
genotype.
resUlTs
effects of TZD on WaT Mass and Fasting 
glucose Do not Differ between WT and 
Ocn-Wnt10b Mice
Circulating adiponectin is decreased in states of obesity and 
glucose intolerance (29), while TZDs modulate both fat mass 
and glucose homeostasis. Therefore, after treating WT and Ocn-
Wnt10b mice with or without rosiglitazone for 2, 4, or 8 weeks, we 
first assessed body mass, fat mass, and fasting glucose, primarily 
as readouts of TZD action but also as parameters that might 
influence circulating adiponectin. While body masses of female 
or male mice did not differ with TZD treatment (Figures 1A,C), 
across both genotypes, TZD was associated with significant loss of 
gonadal WAT (gWAT), a visceral adipose depot, in both females 
(P = 0.027) and males (P = 0.006) (Figures 1B,D). Conversely, 
the mass of inguinal WAT (iWAT), a subcutaneous depot, sig-
nificantly increased with TZD treatment in males (P =  0.002) 
(Figure 1D). Analysis of fasting glucose revealed no effects of TZD 
in female mice (Figure 1E), whereas TZD significantly decreased 
fasting glucose across WT and Ocn-Wnt10b males (Figure 1F). 
These findings are consistent with previous studies demonstrat-
ing that rosiglitazone decreases gWAT mass (26, 27), increases 
subcutaneous WAT (30), and ameliorates hyperglycemia (16); 
FigUre 1 | effects of rosiglitazone on body mass, fat mass, and fasting glucose. Male and female mice were fed a control Western diet only or a Western 
diet supplemented with rosiglitazone for 2, 4, or 8 weeks, as described in Section “Materials and Methods.” (a,c) Body masses of females (a) and males (c) were 
recorded prior to necropsy at 30 weeks of age. (B,D) Masses of iWAT and gWAT were recorded at necropsy for female (B) and male mice (D) and are shown as 
percentage of total body mass. (e,F) Fasting blood glucose, as recorded at 29.5 weeks of age. For (a–F), a significant influence of TZD treatment, across all 
treatment groups, is indicated by † (P < 0.05), †† (P < 0.01) or ††† (P < 0.001). Within each genotype, significant differences between untreated controls (0-week 
TZD) and individual durations of TZD treatment are indicated by ### (P < 0.001). Within each TZD treatment group (0-, 2-, 4-, or 8-week TZD), there were no 
statistically significant differences between WT and Ocn-Wnt10b mice.
5
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however, it is unclear why rosiglitazone influenced iWAT mass 
and fasting glucose in males but not in females. In contrast to 
these effects of rosiglitazone, body mass, WAT mass, or fasting 
glucose did not differ between WT and Ocn-Wnt10b mice within 
each TZD treatment group (Figures 1A–F). Thus, differences in 
peripheral adiposity or glucose homeostasis, which can influence 
circulating adiponectin, did not occur between WT and Ocn-
Wnt10b mice.
6Sulston et al. MAT and TZD-Induced Hyperadiponectinemia
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TZD increases rMaT and cMaT Volume in 
WT Mice, and These effects are Partially 
Blunted in Ocn-Wnt10b Mice
Having characterized these peripheral metabolic parameters, 
we next investigated the impact of TZD on MAT expansion and 
whether this differs between WT and Ocn-Wnt10b mice. To 
do so, we first used an approach based on staining tibiae with 
osmium tetroxide, which covalently binds to unsaturated lipids 
within bone marrow and thereby acts as a strong contrast agent 
for MAT detection by μCT (31). As shown in Figure 2A, osmium 
staining in the proximal diaphysis, corresponding to rMAT, was 
markedly increased in females of both genotypes following 4- or 
8-week TZD treatment. Statistical analyses confirmed that, across 
all groups of females, TZD significantly influenced the volume 
of rMAT, as well as that of cMAT and total MAT (P < 0.0001 for 
each) (Figures 2B,C). Multiple comparisons were then made to 
assess the effect of each duration of TZD treatment in each geno-
type of mice, relative to untreated controls. This revealed that, in 
female WT mice, TZD treatment for 4 or 8 weeks significantly 
increased rMAT volume in proximal tibiae and cMAT volume 
in distal tibiae (Figures  2A,B). Thus, total tibial MAT volume 
was also significantly increased by 4- or 8-week TZD in WT 
females (Figure 2C). Similar effects of TZD were also observed 
in Ocn-Wnt10b females (Figures 2A–C), and rMAT volume did 
not significantly differ between genotypes (Figure 2B). However, 
cMAT volume was markedly lower in Ocn-Wnt10b females within 
each TZD treatment group (Figure 2B). Total tibial MAT volume 
was also significantly decreased in Ocn-Wnt10b compared to WT 
females following 8 weeks’ TZD (Figure 2C).
Compared to the female mice, osmium staining was less 
pronounced in the rMAT of TZD-treated males (Figure  2D). 
Nevertheless, statistical analysis across all groups of males 
revealed a significant influence of TZD on the volumes of rMAT 
(P = 0.0015), cMAT (P = 0.0006), and total MAT (P = 0.0003) 
(Figures  2E,F). Multiple comparisons further revealed that, in 
WT males, treatment with TZD for 8  weeks, but not shorter 
durations, significantly increased volumes of rMAT, cMAT, and 
total MAT (Figures 2E,F). This also occurred for cMAT and total 
MAT, but not rMAT, in Ocn-Wnt10b males (Figures 2E,F). As 
found for female mice, male Ocn-Wnt10b mice had significantly 
decreased cMAT volume compared to their WT counterparts 
(Figure 2E), and this also occurred for total MAT volume in the 
0-, 4-, and 8-week TZD groups (Figure 2F).
cortical Bone ruptures significantly 
Decrease Detectable rMaT Volume
The above observations suggest that Ocn-Wnt10b males 
and females partially resist TZD-induced MAT expansion, 
predominantly as a result of a lower cMAT volume than WT 
mice. Indeed, rMAT volume did not differ between genotypes 
in any of the TZD treatment groups. However, when analyzing 
the μCT scans, we noticed that the decalcified cortical bone had 
ruptured in tibiae from all male mice and in a subset of females. 
The ruptures always occurred in proximal tibial diaphysis, as 
indicated by representative scans of non-ruptured (intact) and 
ruptured tibiae (Figure 3A). Cross sections show that ruptures 
allowed escape of the bone marrow, resulting in decreased 
osmium staining compared to intact tibiae (Figure  3A). This 
loss of signal suggests that the ruptures might have confounded 
measurement of MAT volume. To address this, we quantified 
the volumes of cMAT, rMAT, and total MAT in female tibiae, 
comparing bones from non-TZD-treated mice (all of which 
were intact) with intact or ruptured bones from TZD-treated 
mice. The volume of cMAT did not differ between intact and 
ruptured bones (Figure 3B), indicating that these ruptures did 
not affect detection of cMAT in the distal tibia. However, in 
TZD-treated WT mice, the detectable volume of rMAT and total 
MAT was significantly lower in ruptured compared to intact 
bones (Figure 3B). Indeed, in both WT and Ocn-Wnt10b mice, 
TZD-induced expansion of rMAT and total MAT was strongly 
significant for intact bones, but not when ruptures were present 
(Figure 3B). This impaired rMAT detection likely explains why 
TZD-induced rMAT expansion was less marked in male than in 
female mice (Figure 2B vs. Figure 2E), because all male bones 
were ruptured. Importantly, for intact tibiae, TZD-induced 
expansion of rMAT and total MAT was significantly blunted in 
Ocn-Wnt10b compared to WT mice (Figure 3B). This suggests 
that, in addition to decreased cMAT (Figures  2B,E), Ocn-
Wnt10b mice are at least mildly resistant to rMAT expansion 
during TZD treatment.
adipocyte Transcript expression in Tibiae 
confirms TZD-induced MaT expansion
Given the confounding influence of these bone ruptures, we 
next pursued other approaches to further assess tibial MAT 
content. MAT expansion during CR or rosiglitazone treatment 
has previously been monitored by qPCR analysis of adipocyte 
marker expression in intact bones, including transcripts for 
adiponectin (Adipoq) and fatty acid-binding protein 4 (Fabp4) 
(3, 26). Thus, we next used qPCR to assess Adipoq and Fabp4 
expression in whole tibiae. As shown in Figures 4A–D, across 
all groups of female or males, expression of Adipoq and Fabp4 
was significantly affected by TZD treatment (P <  0.0001 for 
each). Multiple comparisons confirmed that 4- or 8-week 
TZD significantly increased Adipoq in WT males and females 
(Figures 4A,C) and Fabp4 in males and females of each genotype 
(Figures  4B,D). TZD treatment for 2  weeks was also associ-
ated with increased Adipoq in Ocn-Wnt10b males (Figure 4C); 
increased Fabp4 in WT females (Figure  4B); and increased 
Fabp4 in males of each genotype (Figure  4D). Transcript 
expression within each TZD treatment group generally did not 
differ between WT and Ocn-Wnt10b mice, with the exception 
of decreased Adipoq in 4-week TZD females (Figure 4A) and 
decreased Fabp4 in 8-week TZD males (Figure 4D). However, 
two-way ANOVA revealed that genotype significantly influ-
enced Fabp4 in females (P = 0.0184) and males (P = 0.0339), 
while there was a significant genotype–TZD interaction that 
influenced Adipoq expression in females (P  =  0.0193) and 
males (P = 0.0297).
Collectively, these results suggest that TZD increases tibial 
adipocyte content and that there is some level of resistance to 
this effect in Ocn-Wnt10b mice. Thus, together with the osmium 
FigUre 2 | rosiglitazone increases rMaT and cMaT volume in WT mice and cMaT expansion is blunted in Ocn-Wnt10b mice. Male and female tibiae 
were dissected at necropsy. For each mouse, one tibia was decalcified in EDTA, stained with 1% osmium tetroxide, and analyzed by μCT scanning, as described in 
Section “Materials and Methods.” (a,D) Representative μCT scans of stained tibiae from female (a) and male mice (D). The dashed line indicates the tibia–fibula 
junction as the boundary between rMAT and cMAT. (B,c,e,F) For female (B,c) and male mice (e,F), μCT scans were used to determine the volumes of rMAT 
(proximal to tibia–fibula junction), cMAT (distal to tibia–fibula junction), and total MAT (whole tibia), as indicated. In (B,e), volumes of rMAT and cMAT are presented 
on the same y-axis scale. A significant influence of TZD treatment, across all treatment groups, is indicated by † (P < 0.05), †† (P < 0.01) or ††† (P < 0.001). Within 
each genotype, significant differences between TZD-treated mice and untreated controls are indicated by # (P < 0.05), ## (P < 0.01) or ### (P < 0.001). Within 
each TZD treatment group, statistically significant differences between WT and Ocn-Wnt10b mice are indicated by * (P < 0.05), ** (P < 0.01), or *** (P < 0.001).
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FigUre 3 | cortical bone ruptures significantly decrease detectable rMaT volume. All male and some female tibiae had ruptured cortical bone near the 
proximal end, causing a large reduction in signal. (a) Representative 3D models of intact (non-ruptured) and ruptured tibiae from 8-week-TZD-treated females, with 
cross-sectional images showing loss of MAT signal (dark regions within bone marrow cavity). Gray squares across the 3D models indicate the slices from which 
cross-sectional images are taken. Scale bars = 500 μm. (B) Tibiae from female WT or Ocn-Wnt10b mice were categorized into bones from mice untreated with 
TZD, all of which were intact; intact bones from TZD-treated mice; and ruptured bones from TZD-treated mice. The volume of cMAT, rMAT, and total MAT in these 
bones was determined from μCT scans. Statistically significant differences between untreated (intact), TZD-treated (intact), and TZD-treated (ruptured) samples are 
indicated by ## (P < 0.01) or ### (P < 0.001). Within each group, statistically significant differences between WT and Ocn-Wnt10b mice are indicated by  
* (P < 0.05), ** (P < 0.01), or *** (P < 0.001).
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tetroxide analyses of MAT volume (Figures  2 and 3), it seems 
likely that Ocn-Wnt10b mice partially resist TZD-induced MAT 
expansion, but this is not prevented entirely.
TZD induces hyperadiponectinemia  
to a similar extent in WT and  
Ocn-Wnt10b Mice
Given this mild resistance of Ocn-Wnt10b mice to MAT expan-
sion, we next investigated if TZD-induced hyperadiponectinemia 
was altered in these mice. To do so, we used an ELISA to measure 
serum adiponectin concentrations. Across both genotypes 
and all TZD groups, treatment with TZD was associated with 
significantly increased circulating adiponectin (P <  0.0001 for 
males or females) (Figure  5). Genotypic differences were not 
detected in males; however, in females, there was a significant 
influence of genotype (P = 0.0466) and a significant interaction 
between genotype and TZD treatment (P = 0.0248), indicating 
that effects of TZD differ between WT and Ocn-Wnt10b females. 
Consistent with this, multiple comparisons showed significantly 
FigUre 5 | TZD induces hyperadiponectinemia to a similar extent in WT and Ocn-Wnt10b mice. Serum was isolated from mice at 30 weeks of age and 
ELISA used to determine concentrations of total adiponectin in female and male mice, as indicated. For each sex, statistical significance for the influence of TZD 
across all groups, and for differences between TZD-treated and untreated mice (within each genotype) or WT and Ocn-Wnt10b mice (within each TZD group), are 
presented as described for Figure 2.
FigUre 4 | TZD increases adipocyte marker expression in tibiae, suggesting MaT expansion. Male and female tibiae were dissected at necropsy, and total 
RNA was isolated from one tibia of each mouse. Expression of Adipoq (a,c) and Fabp4 transcripts (B,D) in female and male mice was determined by qPCR and is 
presented normalized Ppia mRNA expression. Statistical significance is presented, as described in Figure 2, for the influence of TZD across all groups, and for 
differences between TZD-treated and untreated mice (within each genotype) or WT and Ocn-Wnt10b mice (within each TZD group).
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decreased circulating adiponectin in Ocn-Wnt10b compared 
to WT females following 4 weeks’ TZD (Figure 5). Thus, while 
TZD-induced hyperadiponectinemia was similar between WT 
and Ocn-Wnt10b males, this effect of TZD was mildly blunted in 
female Ocn-Wnt10b mice.
TZD increases adiponectin Protein 
expression in WaT
The above observations demonstrate that, despite having 
significantly decreased cMAT and being partially resistant to 
TZD-induced rMAT expansion, Ocn-Wnt10b mice undergo 
FigUre 6 | rosiglitazone treatment or Wnt10b transgene expression does not alter adiponectin transcript expression in WaT. At necropsy, iWAT and 
gWAT were dissected, and total RNA was isolated from portions of each tissue. Expression of Adipoq in female (a) and male mice (B) was determined by qPCR 
and is presented normalized Ppia mRNA expression. Across all groups, statistically significant effects of TZD are presented as described for Figure 2, while 
significant effects of genotype are described in the text. There were no statistically significant differences between TZD-treated and untreated mice (within each 
genotype) or between WT and Ocn-Wnt10b mice (within each TZD group), as determined by two-way ANOVA.
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hyperadiponectinemia to a similar extent to their WT counter-
parts. Thus, factors beyond MAT might have a greater influence 
over TZD-induced hyperadiponectinemia. To address this pos-
sibility, we next investigated the effects of TZD and genotype on 
adiponectin expression in WAT. In WT and Ocn-Wnt10b females, 
TZD did not influence Adipoq expression in iWAT or gWAT, 
either when comparing individual treatment durations or when 
effects were assessed across all groups (Figure 6A). However, in 
female iWAT, Adipoq transcripts varied significantly by genotype 
(P = 0.0095), with expression diverging as TZD duration increased 
(Figure 6A). Given that Wnt10b transgene expression is restricted 
to osteoblasts, this genotypic difference in WAT was unexpected. 
Across all groups of males, TZD treatment had a minor influence 
on Adipoq transcript levels in both iWAT and gWAT (P = 0.0269 
and P =  0.0461, respectively), although multiple comparisons 
found no significant effects of TZD between individual treatment 
groups (Figure  6B). As for females, male iWAT also exhibited 
genotypic variation (P =  0.0096), although in this case Adipoq 
expression tended to be greater in Ocn-Wnt10b than in WT mice 
(Figure 6B).
These findings show that WAT Adipoq expression is influenced 
only modestly by TZD, in contrast to the marked TZD-mediated 
increases in circulating adiponectin (Figure 5). Indeed, our above 
observations in female mice are consistent with previous reports 
demonstrating that TZDs can increase circulating adiponectin 
without increasing Adipoq expression in WAT (23, 24). However, 
other studies have reported a disparity between adiponectin 
expression at the transcript and protein level (32, 33). Therefore, 
we next used fluorescence-based immunoblotting to detect and 
quantify adiponectin protein expression. As shown in Figure 7A, 
across all groups of female mice, there was a significant influence 
of TZD on adiponectin protein expression in iWAT and gWAT 
(P  <  0.0001 for both), with adiponectin typically increased 
in WAT of TZD-treated mice compared to untreated controls. 
Multiple comparisons further confirmed that, for females of each 
genotype, TZD treatment for 2 or 8 weeks significantly increased 
adiponectin protein in gWAT or iWAT, respectively (Figure 7A). 
As for females, across all groups of male mice, TZD had a signifi-
cant influence on adiponectin protein in iWAT (P = 0.004) and 
gWAT (P = 0.0004) (Figure 7B). Based on multiple comparisons, 
adiponectin was significantly elevated in iWAT and gWAT of 
WT males after 2 weeks of TZD, and in gWAT of Ocn-Wnt10b 
males after 2 or 4  weeks of TZD (Figure  7B). These results 
demonstrate that rosiglitazone significantly increases expression 
FigUre 7 | rosiglitazone increases adiponectin protein expression in WaT in a depot- and sex-specific manner. At necropsy, iWAT and gWAT were 
dissected, and total protein was isolated from portions of each tissue. Lysates were separated by SDS-PAGE and expression of adiponectin protein determined by 
immunoblotting; β-actin expression was analyzed as a loading control. Immunoblots shown in (a,B) are representative of three mice per group. Samples from 
Ocn-Wnt10b mice are labeled “Tg.” Band intensities from these blots and further blots of the remaining samples were quantified using Image Studio Lite software. 
Adiponectin expression was then normalized to expression of β-actin for (a) Males and (B) Females, with representative blots shown beneath. For each sex, 
statistically significant differences between TZD-treated and untreated mice (within each genotype) or between WT and Ocn-Wnt10b mice (within each TZD group) 
are presented as described for Figure 2.
11
Sulston et al. MAT and TZD-Induced Hyperadiponectinemia
Frontiers in Endocrinology | www.frontiersin.org September 2016 | Volume 7 | Article 128
of adiponectin protein in WAT of female and male mice. Thus, it 
seems likely that, with this regimen of rosiglitazone treatment, 
WAT makes at least a partial contribution to TZD-induced 
hyperadiponectinemia.
TZD induces UcP1 Protein expression in 
BaT but not in WaT or Tibiae
While these studies focused on the relationship between MAT 
and adiponectin, they also provided the opportunity to assess 
other properties of MAT; indeed, it remains unclear to what 
extent MAT’s characteristics overlap with those of WAT and BAT. 
The key function of BAT is to mediate adaptive thermogenesis 
via uncoupled respiration, which is dependent on expression of 
uncoupling protein 1 (UCP1). TZDs dose-dependently increase 
UCP1 protein and Ucp1 transcripts in BAT and can upregulate 
Ucp1 in WAT and whole tibiae (26, 34). Based on the latter, it has 
been suggested that MAT may have BAT-like characteristics (26). 
However, others have argued that elevated Ucp1 expression alone, 
without assessment of UCP1 protein, is insufficient evidence for 
a tissue’s thermogenic capacity (35). Indeed, the relative protein 
expression of UCP1 between MAT and BAT remains to be firmly 
established. Thus, to further study the BAT-like properties of 
MAT, we next analyzed UCP1 expression in BAT, WAT, and 
tibiae, both at the transcript and protein level.
FigUre 8 | rosiglitazone increases UcP1 mrna and protein in BaT not in WaT or tibiae. Total RNA and protein were isolated from interscapular BAT, 
gWAT, iWAT, and whole tibiae. (a,B) Ucp1 transcript expression in each tissue of female (a) and male mice (B) was quantified by qPCR and normalized to 
expression of Ppia mRNA. In each tissue, statistically significant differences between TZD-treated and untreated mice (within each genotype) or between WT and 
Ocn-Wnt10b mice (within each TZD group) were determined by two-way ANOVA and are presented as described for Figure 2. (c) Protein lysates from BAT were 
separated by SDS-PAGE and expression of UCP1 protein determined by immunoblotting; β-actin expression was analyzed as a loading control. Immunoblots are 
representative of three mice per group. Samples from Ocn-Wnt10b mice are labeled “Tg.” UCP1 protein could not be detected in gWAT, iWAT, or tibiae (data not 
shown).
12
Sulston et al. MAT and TZD-Induced Hyperadiponectinemia
Frontiers in Endocrinology | www.frontiersin.org September 2016 | Volume 7 | Article 128
As shown in Figures 8A,B, across all groups of female or male 
mice, TZD strongly influenced Ucp1 expression in BAT (females, 
P =  0.0002; males, P <  0.0001). Multiple comparisons further 
confirmed that, relative to untreated controls, each duration of 
TZD significantly increased BAT Ucp1 in males of each genotype 
(Figure 8B), while this also occurred for females with 2 weeks’ TZD 
treatment (Figure  8A). Across-group effects of TZD were also 
detected in female gWAT (P = 0.014), female tibiae (P < 0.0001), 
male gWAT (P = 0.0051), and male tibiae (P = 0.0017), wherein 
TZD-treated groups typically had greater Ucp1 expression than 
untreated controls (Figures  8A,B). Analysis of genotypic dif-
ferences via multiple comparisons confirmed that, relative to 
untreated mice, Ucp1 was significantly elevated in Ocn-Wnt10b 
female tibiae or gWAT after 4 or 8 weeks’ TZD, respectively, and 
in WT male gWAT, after 8 weeks’ TZD (Figures 8A,B). Each of 
these groups also had significantly greater Ucp1 expression than 
their untreated WT or Ocn-Wnt10b counterparts, respectively; 
however, such genotypic differences were uncommon, and geno-
type generally did not influence Ucp1 expression in any of the 
tissues analyzed.
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These data demonstrate that rosiglitazone increases Ucp1 
expression in BAT, gWAT, and tibiae, consistent with results in 
previous studies (26, 34). However, relative to expression in BAT, 
Ucp1 expression in untreated mice was over 500-fold lower in 
gWAT, 1,500-fold lower in iWAT, and 10,000-fold lower in tibiae 
(Figures 8A,B). Thus, even with TZD treatment, Ucp1 expression 
in these tissues is negligible, raising questions over its functional 
relevance. To further address this, we next analyzed UCP1 expres-
sion at the protein level. As shown in Figure 8C, in females and 
males of either genotype, TZD robustly increased UCP1 expres-
sion in BAT; however, in gWAT, iWAT, or whole tibiae, we could 
not detect UCP1 protein expression (data not shown). Together, 
these observations suggest that MAT is unlikely to possess the 
thermogenic properties of BAT.
DiscUssiOn
Herein, we pursued studies in Ocn-Wnt10b mice to investigate 
the hypothesis that MAT expansion contributes to TZD-induced 
hyperadiponectinemia. We found that, regardless of TZD treat-
ment, Ocn-Wnt10b mice have significantly less cMAT than WT 
mice and likely resist TZD-induced rMAT accumulation. Despite 
this loss of cMAT and mild resistance to rMAT expansion, cir-
culating adiponectin is generally similar between WT and Ocn-
Wnt10b mice. Moreover, we found that TZD significantly increases 
adiponectin protein expression in WAT. Together, these findings 
suggest that WAT, rather than MAT, is the key mediator of TZD-
induced hyperadiponectinemia, at least under these conditions of 
TZD treatment. However, as discussed in Section “Contribution 
of MAT and WAT to TZD-Induced Hyperadiponectinemia,” fur-
ther consideration of these findings suggests that MAT makes at 
least some contribution to TZD-induced hyperadiponectinemia. 
As a secondary aim, we also addressed the hypothesis that MAT 
has BAT-like properties. We found that, in contrast to BAT, UCP1 
protein is undetectable in tibiae, suggesting that MAT is unlikely 
to have the thermogenic capacity of BAT.
As further discussed below, these findings shed new light on 
the function of MAT and have implications worth considering for 
future MAT research.
contribution of MaT and WaT to  
TZD-induced hyperadiponectinemia
We previously identified MAT as a source of increased circulat-
ing adiponectin during CR, a conclusion based, in part, on the 
finding that Ocn-Wnt10b mice resist both CR-associated MAT 
expansion and hyperadiponectinemia (2, 3).
Herein, we find that, regardless of TZD treatment, cMAT 
volume is significantly lower in Ocn-Wnt10b than in WT mice. 
Unfortunately, tibial ruptures confounded measurement of rMAT 
volume; however, analysis of intact tibiae, without ruptured sam-
ples, suggests strongly that Ocn-Wnt10b mice also partially resist 
rMAT accumulation in response to TZD treatment. Despite this 
loss of cMAT and mild resistance to rMAT expansion, circulating 
adiponectin is generally similar between WT and Ocn-Wnt10b 
mice. Superficially, this suggests that MAT expansion per  se 
does not contribute to hyperadiponectinemia under these TZD 
treatment conditions. However, this conclusion is less certain 
when several other key factors are taken into account.
One such factor is the likely contribution of WAT. Unlike 
during CR, adiponectin protein expression in WAT is increased 
under these conditions of TZD treatment, which may override any 
effects of suppressed MAT expansion. These increases are more 
pronounced for adiponectin protein than for Adipoq transcripts, 
with TZD affecting the Adipoq transcripts only in male WAT 
(Figure 6). These findings echo previous reports of sex-specific 
differences in WAT adiponectin expression, and of a disconnect 
between adiponectin expression at the transcript and protein 
level (32, 33). Notably, these effects on WAT are inconsistent 
with the finding that TZDs can increase circulating adiponectin 
without increasing adiponectin expression in WAT (23, 24). This 
disparity is likely a result of the higher dose of rosiglitazone used 
in our study. Indeed, WAT adiponectin expression is unaltered 
by lower TZD doses (24, 36) but significantly increased at higher 
rosiglitazone concentrations (18). Thus, as discussed further 
below (“Implications of TZD Dose on the Capacity of Ocn-Wnt10b 
Mice to Resist MAT Expansion and Hyperadiponectinemia”), a 
lower dose of rosiglitazone would likely be required if we were to 
further investigate the contribution of MAT to TZD-associated 
hyperadiponectinemia.
Considering these findings, it seems likely that WAT makes 
at least some contribution to hyperadiponectinemia under these 
conditions of rosiglitazone treatment. However, the effect of 
TZD on WAT adiponectin expression (Figures 6 and 7) is far less 
consistent and pronounced than that which occurs for circulating 
adiponectin concentrations (Figure 5). In contrast, these changes 
in circulating adiponectin are closely reflected by the increases 
in tibial adiponectin expression (Figure 4). For example, when 
comparing Ocn-Wnt10b and WT mice, circulating adiponectin 
is lower only in the 4-week TZD females (Figure 5); hence, it is 
striking that this is also the only group in which tibial adiponectin 
expression is lower in Ocn-Wnt10b mice (Figure 4A). Together, 
these observations show that circulating adiponectin is closely 
associated with tibial adiponectin expression and less tightly 
associated with gross changes in rMAT and cMAT volume. This 
underscores the importance of analyzing MAT through multiple 
approaches, including transcriptional markers, rather than 
focusing solely on MAT volume via osmium tetroxide staining. 
Perhaps, more importantly, this close association suggests that 
adiponectin production from MAT contributes, at least in part, 
to TZD-induced hyperadiponectinemia.
implications of TZD Dose on the capacity 
of Ocn-Wnt10b Mice to resist MaT 
expansion and hyperadiponectinemia
Previous studies have used a wide range of doses of rosiglita-
zone to investigate its impact on adiponectin or bone marrow 
adiposity. For example, Nawrocki et al. treated mice with 10 mg/
kg/day to examine the effects on circulating adiponectin and 
glucose homeostasis (20), while 20 mg/kg/day was used in two 
more recent studies investigating effects of rosiglitazone on bone 
marrow adiposity (26, 27). A much lower dose of 3 mg/kg/day 
was also found to cause MAT expansion in mice, but whether 
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this promotes hyperadiponectinemia was not reported (28, 37). 
Thus, in the present study, we used 15 mg/kg/day to ensure robust 
effects on MAT and circulating adiponectin. As in the above 
studies (26–28), we did so by administering rosiglitazone in the 
diet, based on measurements of body mass and estimated daily 
food intake. However, because of variation in body masses and 
daily food consumption, some mice may have exceeded the target 
dose of 15  mg/kg/day. As discussed above, this relatively high 
dose may explain the increased adiponectin expression in WAT, 
thereby complicating interpretation of any contribution from 
MAT. Such high doses may also have overwhelmed the ability of 
Ocn-Wnt10b mice to more robustly resist MAT expansion. Thus, 
a lower rosiglitazone dose may limit these confounding effects 
and thereby be more suitable for addressing our hypothesis in 
Ocn-Wnt10b mice.
limitations of Ocn-Wnt10b Mice as a 
Model resistant to MaT expansion
One reason that we have not pursued such follow-up studies 
is that Ocn-Wnt10b mice may be too limited a model in which 
to robustly address MAT’s endocrine functions. For example, 
while CR- or TZD-induced MAT expansion is blunted in 
these mice, such expansion is still marked in comparison 
to untreated Ocn-Wnt10b controls (Figures  2 and 3) (3). 
Moreover, distal tibiae of Ocn-Wnt10b mice remain laden with 
MAT (Figures  2A,D) and, while cMAT volume is lower in 
Ocn-Wnt10b mice, this likely reflects restrictions imposed by 
decreased bone marrow volume (3), rather than resulting from 
a direct inhibition of adipogenesis. Thus, as we have recently 
argued elsewhere (7), future research of MAT would benefit 
enormously from development of new mouse models that 
more robustly resist MAT formation, developmentally and/or 
in response to CR, TZDs, or other stimuli that promote MAT 
expansion.
confounding effects of Bone ruptures on 
Osmium Tetroxide-Based rMaT analysis
The present study reveals that cortical bone ruptures can con-
found osmium-based MAT detection. This issue, which has not 
been reported previously, provides further support for taking a 
multifaceted approach to MAT analysis. While TZDs can cause 
bone loss and fractures (38), it is unlikely that the ruptures 
occurred in vivo over the course of rosiglitazone treatment: such 
an injury would have dramatically impacted mobility and behav-
ior of the mice, which was not apparent during daily inspections; 
and the ruptures also occurred in tibiae of males untreated with 
rosiglitazone, demonstrating that they are not a consequence 
of TZD treatment. Instead, it is likely that ruptures occurred 
ex vivo as a result of methodological issues. In particular, after 
fixing tibiae in formalin post-necropsy there was a very long time 
span, ~30 months, before most of these bones were decalcified 
and analyzed by osmium tetroxide staining. This holdup largely 
resulted from delays associated with one of our lead authors 
moving to a new institution, during which time the fixed tibiae 
were stored in PBS at 4°C and shipped by air from the USA to the 
UK. Although these storage conditions would not be expected to 
promote cortical ruptures, it is notable that no ruptures occurred 
in a subset of female tibiae that were stored in PBS for a shorter 
duration (~12 months), without air transport, before decalcifica-
tion and osmium analysis. Moreover, at both the University of 
Michigan and the University of Edinburgh, we have analyzed 
hundreds of osmium-stained mouse bones from other studies, 
none of which has undergone such long-term storage or air 
transport, and among which no ruptures have ever been detected. 
Thus, one possibility is that exposure to low air pressure during 
air transport can cause a pressure differential that promotes bone 
ruptures. It remains possible that other factors also contributed 
to this phenomenon; however, our findings strongly suggest that 
fixed bones should not undergo long-term storage or exposure 
to low atmospheric pressure if MAT volume is to be determined 
accurately using osmium tetroxide staining.
BaT-like Thermogenic Function is 
Unlikely in MaT
There is extensive interest in “beige” or “brite” (brown-in-white) 
adipocytes, which develop in WAT in response to diverse external 
stimuli, including cold exposure or TZD treatment, and which 
share some properties of brown adipocytes (39–41). This so-
called “browning” of WAT can increase energy consumption 
and may thereby contribute to TZD-associated improvement 
in metabolic health. Therefore, whether MAT can also undergo 
browning or has BAT-like characteristics has been a subject of 
some interest. Krings et al. found that, in mice treated for 4 weeks 
with rosiglitazone (20 mg/kg/day), transcript expression of brown 
adipocyte markers is increased in tibiae, supporting the possibil-
ity that MAT has BAT-like characteristics (26). This is consistent 
with our finding that rosiglitazone influences tibial Ucp1 mRNA 
expression (Figure 8). However, Krings et al. further highlighted 
that, compared to BAT, Ucp1 expression is 16,000-fold lower in 
tibiae, which agrees closely with our data showing a 10,000- to 
25,000-fold decrease in tibiae compared to BAT. In addition, even 
with rosiglitazone treatment, we find that Ucp1 transcripts remain 
400- to 7,000-fold lower in tibiae than in BAT (Figures 8A,B). 
Crucially, at this level of Ucp1 expression, we could not detect 
UCP1 protein, whereas rosiglitazone-induced increases in UCP1 
protein in BAT are readily detectable (Figure 8C).
UCP1 is the hallmark of brown adipocytes and the key media-
tor of adaptive thermogenesis, and therefore the above findings 
strongly suggest that bone marrow adipocytes are unlikely to 
possess BAT-like thermogenic properties. One limitation of 
our study, and that of Krings et  al., is that we analyzed whole 
bones rather than isolated marrow adipocytes. However, both 
brown and beige adipocytes are further defined by their high 
mitochondrial content and the multilocular morphology of their 
lipid droplets (41), neither of which is observed in bone marrow 
adipocytes (3, 4, 12, 42). This raises further doubts about the 
notion that MAT has BAT-like characteristics, an issue that we 
recently discussed in greater depth elsewhere (5). Nevertheless, it 
remains possible that, under a different TZD treatment regimen 
or in response to other stimuli, MAT is capable of undergoing 
browning. Indeed, while we were unable to detect UCP1 protein 
in WAT or whole tibiae, previous studies have detected UCP1 in 
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WAT following TZD treatment (41). Moreover, effects of TZDs 
on Ucp1 expression in BAT are dose-dependent (34). This sup-
ports the possibility that TZD-mediated browning of WAT and 
MAT requires an optimal regimen of TZD treatment, in which 
case the conditions in our study may simply have been unsuitable 
for inducing a browning response. Thus, there is ample scope for 
future studies to further investigate whether MAT has BAT-like 
properties, both at the molecular and functional levels.
Other strengths and limitations  
of This study
This study is the first to address the novel hypothesis that MAT 
contributes to hyperadiponectinemia in conditions beyond CR. 
The experimental design is strengthened by including both male 
and female mice, as well as by analysis of several durations of TZD 
treatment. The discovery of the confounding effects of cortical 
ruptures is partly a strength, in that it highlights an important 
technical consideration for future MAT research; however, pres-
ently this was a limitation because it prevented thorough meas-
urement of rMAT volume. As discussed above, another limitation 
is that the dose of rosiglitazone may have been too high, and may 
have varied slightly between mice because of differences in body 
mass and daily food intake. Administration of lower doses by 
daily injection or oral gavage could be one approach to overcome 
this issue. Finally, a key limitation of this study is that our findings 
are based on only a single cohort of mice. Ideally, these experi-
ments would be repeated in a second cohort, with particular care 
taken to avoid cortical ruptures; this would allow more robust 
determination of rMAT volume in Ocn-Wnt10b mice. However, 
as noted above (“Limitations of Ocn-Wnt10b Mice as a Model 
Resistant to MAT Expansion”), Ocn-Wnt10b mice may not 
be sufficiently robust as a model of impaired MAT formation. 
For example, adipocyte marker expression in tibiae is generally 
similar between WT and Ocn-Wnt10b mice (Figure  4). This 
limitation of the Ocn-Wnt10b model undermines the rationale 
for repeating the present studies in a second cohort. Instead, we 
feel strongly that it would be more productive and scientifically 
beneficial to focus efforts on developing new mouse models that 
more robustly resist MAT expansion. Such models could then 
be used to better address the present hypothesis, as well as other 
aspects of MAT function.
Beyond these particular issues, one broader limitation is that 
our experiments were based only in mice; it remains unclear if 
the relationship between TZD-induced MAT expansion and 
hyperadiponectinemia also exists in humans. It is well established 
that TZDs increase circulating adiponectin in humans (16), but 
their effects on MAT are less clear. Indeed, one study finds that 
rosiglitazone decreases bone marrow adiposity in the lumbar 
vertebrae (43), whereas a more recent report finds that pioglita-
zone, another TZD, increases femoral and lumbar vertebral bone 
marrow adiposity (44). Unfortunately, neither of these studies 
assessed circulating adiponectin, and there remain very few clini-
cal studies assessing the effect of TZDs on MAT. Thus, there is a 
strong rationale for future research to establish how TZDs affect 
MAT accumulation in humans and whether this is associated 
with changes in circulating adiponectin.
cOnclUsiOn
There are four main conclusions from our study. First, under these 
TZD treatment conditions, it is likely that both WAT and MAT 
make some contribution to TZD-induced hyperadiponectinemia. 
Second, UCP1 expression in MAT is negligible, and therefore 
MAT is unlikely to have the thermogenic capacity of BAT. Third, 
cortical bone ruptures confound measurement of MAT volume 
by osmium tetroxide staining, and therefore care must be taken 
when processing bones for such analysis. Moreover, osmium-
based assessment of MAT volume can differ from measurement 
of MAT content based on expression of bone marrow adipocyte 
transcripts; hence, multiple approaches should be used to assess 
MAT content, including analysis of molecular markers, rather 
than relying solely on osmium tetroxide staining. Finally, while 
Ocn-Wnt10b mice have been useful as a model resistant to MAT 
formation, development of more robust loss-of-MAT models 
would be of great benefit to future MAT research.
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